Releasing IoM Drug Safety Report Could Be Early On Von Eschenbach’s Watch
This article was originally published in The Tan Sheet
Executive Summary
One of Andrew von Eschenbach's first major steps as FDA commissioner will likely be a release of the agency task force response to the Institute of Medicine's (IoM) recommendations to improve drug safety oversight